Antihypertensive efficacy of amlodipine and losartan after two 'missed' doses in patients with mild to moderate essential hypertension

Journal of International Medical Research

Volumn 35, Issue 6, 2007, Pages 762-772

  Ribeiro, A B ^a,j   Mion Jr , D ^b   Marin, M J ^c   Majul, C ^d   Botero, R ^e   Lopez N R ^f   Gonzalez, S ^g   Izurieta, H ^h   Francischetti, E A ⁱ  

^a HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Policlinico Bancario   (Argentina)

^d Hospital Santojanni Buenos Aires   (Argentina)

^e Clinica Medellin   (Colombia)

^f Centro Medico Docente La Trinidad   (Venezuela)

^g Durango General Hospital   (Mexico)

^h Centro Médico Alemania   (Ecuador)

ⁱ Society of Critical Care Medicine of Rio de Janeiro   (Brazil)

^j NONE   (Brazil)

more..

Author keywords

Ambulatory blood pressure monitoring; Amlodipine; Antihypertensive drugs; Drug holiday; Hypertension; Losartan; Therapeutic coverage

Indexed keywords

AMLODIPINE; LOSARTAN; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 36949012977     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500604     Document Type: Article

References (25)

1. World Health Organization: The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Available at: http://www.who.int/whr/ 2002/en/inclex.html (last accessed 13 July 2007).
2. Mallion JM, Genès N, Vaur L, et al: Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study. J Hum Hypertens 2001; 15: 841-848.
3. Swales JD: Current clinical practice in hypertension: the Eisberg (Evaluation and Intervention for Systolic Blood Pressure Elevation - Regional and Global) project. Am Heart J 1999; 138: s231-s237.
4. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee an Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
5. Berlowitz DR, Ash AS, Hickey EC, et al: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-1963.
6. Claxton AJ, Cramer J, Pierce C: A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
7. Flack JM, Novikov SV, Ferrario CM: Benefits of adherence to anti-hypertensive drug therapy. Eur Heart J 1996; 17(suppl A): 16-20.
8. Fagard R, Staessen JA, Thijs L: The relationships between left ventricular mass and daytime and nighttime blood pressures: a meta-analysis of comparative studies. J Hypertens 1995; 13: 823-829.
9. Verdecchia P, Clement D, Fagard R, et al: Taskforce III: Target-organ damage morbidity and morality. Blood Press Monit 1999; 4: 303-317.
10. Khattar RS, Senior R, Swales JD, et al: Value of ambulatory intra-arterial blood pressure monitoring in the long-term prediction of left ventricular hypertrophy and carotid atherosclerosis in essential hypertension. J Hum Hypertens 1999; 13: 111-116.
11. Khattar RS, Swales JD, Banfield A, et al: Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pressure monitoring in essential hypertension. Circulation 1999; 100: 1071-1076.
12. Kikuya M, Hozawa A, Ohokubu T, et al: Prognostic significance of blood pressure and heart rate variabilities. The Ohasama Study. Hypertension 2000; 36: 901-906.
13. Mancia G, Parati, G, Hennig M, et al: Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001; 19: 1981-1989.
14. Burges RA: Review of the pharmacology of amlodipine. J Cardiovasc Pharmacol 1992; 20(suppl A): S1-S5.
15. Biston P, Melot C, Degaute JP, et al: Prolonged antihypertensive effect of amlodipine: a prospective double-blind randomized study. Blood Press 1999; 8: 43-48.
16. Pfizer Inc: Norvasc® (package insert). New York: Pfizer Inc, 2003.
17. Merck & Co, Inc: Cozaar® (package insert). Whitehouse Station: Merck & Co, Inc, 1995.
18. Kroon AA, de Leeuw PW, Degaute J-P, et al. Amlodipine and losartan in the treatment of elderly hypertensives including persistence of effect in case of missed doses. Am J Hypertens 2002; 15: 115A.
19. Tiebel R, Vahlbruch A, Stapff M: Efficacy, safety, and effects on hypertension-associated symptoms of losartan, alone or in combination with hydrochlorothiazide, versus amlodipine in patients with mild-to-moderate hypertension. Curr Ther Res 1998; 59: 325-340.
20. Dahlöf B, Lindholm LH, Carney O, et al: Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. J Hypertens 1997; 15: 1327-1335.
21. Hemández-Hernández R, Armas de Hernández MJ, Armas-Padilla MC, et al: The effects of missing a dose of enalapril versus amlodipine on ambulatory blood pressure. Blood Press Monit 1996; 1: 121-126.
22. Zannad F, Bernaud CM, Fay R: Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension. J Hypertens 1999; 17: 137-146.
23. Hu D, Zhao X, He X, et al: Effect of 'drug holiday' on blood pressure control: a randomized double-blind comparative trial of amlodipine versus felodipine extended release in Chinese patients with mild to moderate essential hypertension. Heart Drug 2001; 1: 77-82.
24. Hernández-Hernández R, Armas-Hernández MJ, Chourio JAC, et al: Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. Blood Press Monit 2001; 6: 47-57.
25. Leenen FH, Fourney A, Notman G, et al: Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41: 83-88.